Harmony Biosciences
HRMY
247 hedge funds and large institutions have $1.82B invested in Harmony Biosciences in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 128 increasing their positions, 48 reducing their positions, and 25 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 48
142% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $1.75M
60% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 25
6% more funds holding
Funds holding: 233 → 247 (+14)
4.28% more ownership
Funds ownership: 88.23% → 92.5% (+4.3%)
9% less capital invested
Capital invested by funds: $2.01B → $1.82B (-$190M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$49.8M |
| 2 |
BlackRock
New York
|
+$45.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$41.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
Valor Management
Chicago,
Illinois
|
-$158M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$104M |
| 3 |
CCM
Cutter Capital Management
New York
|
-$15.1M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.9M |
| 5 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$3.88M |
HRMY Hedge Fund Activity: Q4 2024 in Review
247 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2024, worth a combined $1.82B — down 9.5% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new HRMY positions and 25 closed out — a net gain of 15 holders — while 128 added to existing stakes and 48 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $49.8M. The largest seller was Valor Management, cutting an estimated $158M.
- 247 institutional investors held Harmony Biosciences (HRMY) as of Q4 2024, up from 233 in Q3 2024.
- Funds reported $1.82B of Harmony Biosciences stock for Q4 2024, down 9.5% quarter-over-quarter.
- 40 funds opened new Harmony Biosciences positions in Q4 2024 and 25 closed out, a net change of +15 holders.
- The largest Harmony Biosciences buyer in Q4 2024 was Deep Track Capital, an estimated $49.8M added.
- The largest Harmony Biosciences seller in Q4 2024 was Valor Management, an estimated $158M sold.
Based on aggregated 13F filings for Q4 2024.